Povorcitinib 75 mg achieved high-threshold lesion clearance by week 12, including 100% draining-tunnel reduction in 12%–57% and total abscess clearance in 22%–62% of participants. Phase 3 data show ...
A new study published in JMIR Dermatology shows that TikTok has become a major source of education and support for people ...
The massive cuts to science, global health, and HIV programs that unfolded in 2025 triggered a crisis with worldwide repercussions. The dissolution of USAID, the shutdown of PEPFAR, and the suspension ...
Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe Improvements with remibrutinib observed as early as Week 1 in REMIX 1 & 2, with ...
Bimekizumab yields clinically meaningful improvements in the severity of hidradenitis suppurativa over 48 weeks, shifting most patients to a mild disease, a pooled analysis of two trials shows.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results